LABORATORY RESEARCH Targeting Matriptase in Breast Cancer Abrogates Tumor Progression via Impairment of Stromal-Epithelial Growth Factor Signaling Scientists demonstrated by genetic deletion and silencing that the proliferation impairment in matriptase-deficient breast cancer cells is caused by their inability to initiate activation of the c-Met signaling pathway in response to fibroblast-secreted pro-HGF. [Nat Commun] Abstract Modelling Breast Cancer Requires Identification and Correction of a Critical Cell Lineage-Dependent Transduction Bias Researchers present an analytical method for quantifying transductional differences between cell types and an optimized protocol for transducing unsorted primary human breast cells in context. [Nat Commun] Full Article p63/MT1-MMP Axis Is Required for In Situ to Invasive Transition in Basal-Like Breast Cancer The authors report that expression of membrane-type 1 (MT1)-matrix metalloproteinase (MMP) increased during breast cancer progression at the in situ to invasive breast carcinoma transition. MT1-MMP is required for basement membrane (BM) transmigration of MCF10DCIS.com breast adenocarcinoma cells and is overexpressed in cell clusters overlying focal BM disruptions and at the invasive tumor front. [Oncogene] Abstract CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer Researchers investigated the role of estrogen dependent chemokine expression and subsequent cancer growth in human tissues and experimental breast cancer models. Estrogen exposure and targeted therapies were assessed in immune competent PyMT murine breast cancer, orthotopic human breast cancers in nude mice, cell culture of cancer cells, and freshly isolated human macrophages. [Clin Cancer Res] Abstract | Full Article The Proteomic Landscape of Triple-Negative Breast Cancer To discover molecular features of triple-negative breast cancer, scientists performed quantitative proteomics analysis of twenty human-derived breast cell lines and four primary breast tumors to a depth of more than 12,000 distinct proteins. They used this data to identify breast cancer subtypes at the protein level and demonstrate the precise quantification of biomarkers, signaling proteins, and biological pathways by mass spectrometry. [Cell Rep] Full Article | Graphical Abstract | Press Release Stearoyl-CoA Desaturase 1 and Paracrine Diffusible Signals Have a Major Role in the Promotion of Breast Cancer Cell Migration Induced by Cancer-Associated Fibroblasts Fibroblast/breast cancer cell co-cultures were set up to investigate the influence of normal fibroblasts and cancer-associated fibroblasts on gene and protein expression of stearoyl-CoA desaturase 1, the main enzyme regulating membrane fluidity, as well as on the protein level and activity of its transcription factor, the sterol regulatory element-binding protein 1, in MCF-7 and MDA-MB-231 cells. [Br J Cancer] Full Article Targeting Breast Cancer Stem Cells in Triple-Negative Breast Cancer Using a Combination of LBH589 and Salinomycin Scientists investigated the efficacy of combining a histone deacetylase inhibitor and a breast cancer stem cells-targeting agent (salinomycin) as a novel combination therapy for triple-negative breast cancer. [Breast Cancer Res Treat] Abstract miR-218 Targets Survivin and Regulates Resistance to Chemotherapeutics in Breast Cancer MicroRNA (miRNA) profiling of two drug-resistant breast cancer cell models indicated that miR-218 was down-regulated in both MCF-7/A02 and CALDOX cells. Ectopic expression of miR-218 resensitized both drug-resistant cell lines to doxorubicin and taxol due to an increase in apoptosis. [Breast Cancer Res Treat] Abstract Impact of Kinesin Eg5 Inhibition by 3,4-Dihydropyrimidin-2(1H)-One Derivatives on Various Breast Cancer Cell Features Researchers identified five 3,4-dihydropyrimidin-2(1H)-one derivatives with pronounced inhibitory activity on Eg5 motor protein interfering with the proper mitotic spindle assembly during cell division. These compounds impair the correct conclusion of cell cycle of the breast cancer cells and showed to be selective for tumor cells. [BMC Cancer] Abstract | Full Article CLINICAL RESEARCH Pazopanib plus Weekly Paclitaxel versus Weekly Paclitaxel Alone for Platinum-Resistant or Platinum-Refractory Advanced Ovarian Cancer (MITO 11): A Randomized, Open-Label, Phase II Trial Investigators assessed the effect of adding pazopanib to paclitaxel for patients with platinum-resistant or platinum-refractory advanced ovarian cancer. [Lancet Oncol] Abstract Fulvestrant with or without Selumetinib, a MEK 1/2 Inhibitor, in Breast Cancer Progressing after Aromatase Inhibitor Therapy: A Multicenter Randomized Placebo-Controlled Double-Blind Phase II Trial, SAKK 21/08 Scientists assessed the efficacy and safety of fulvestrant with selumetinib, a MEK 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor. [Eur J Cancer] Abstract |